BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses. BioSante sold an aggregate of approximately 7.1 million shares of its common stock and warrants to purchase up to approximately 3.55 million shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock, was sold for a purchase price of $2.1025, a premium to the closing bid price on Friday June 18, 2010, as reported by the NASDAQ Stock Market.
The warrants to purchase additional shares are exercisable at an exercise price of $2.45 per share beginning on June 23, 2010 and will expire on June 22, 2015. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be primarily used to fund BioSante's LibiGel Phase III clinical study program and for general corporate purposes.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (NASDAQ: RODM), acted as the exclusive placement agent for the transaction. JMP Securities LLC, Oppenheimer & Co. Inc. and Trout Capital LLC acted as financial advisors.
SickKids study offers new path for pediatric rare disease clinical trials